Literature DB >> 26180619

Pleomorphic Adenoma with Sarcomatous Change in a Lacrimal Gland.

Kyoung-Su Sung1, Dae-Cheol Kim2, Hee-Bae Ahn3, Young-Jin Song1.   

Abstract

A 69-year-old man was referred with left exophthalmos. Computed tomographic (CT) findings detected a well-circumscribed mass in the left side of the intraorbital cavity. At that time, he refused the further evaluation and treatment. About three years later, the size of the mass had enlarged, and the patient's symptoms were getting worse. The mass was completely removed with frontotemporal craniotomy and superolateral orbitotomy. In operative findings, the mass had originated in the lacrimal gland and was well-encapsulated without invasion to the surrounding tissue. In the pathologic findings, the tumor consisted of pleomorphic adenoma with osteosarcomatous change of stromal components. Postoperatively, the adjuvant radiotherapy was done four weeks later. The patient's symptoms were improved. The pleomorphic adenoma with osteosarcomatous change is extremely rare and appropriate treatment is not clearly established. We would like to report this rare case with a review of the literature.

Entities:  

Keywords:  Lacrimal gland; Malignant mixed tumor; Pleomorphic adenoma; Sarcoma

Year:  2015        PMID: 26180619      PMCID: PMC4502248          DOI: 10.3340/jkns.2015.57.6.473

Source DB:  PubMed          Journal:  J Korean Neurosurg Soc        ISSN: 1225-8245


  22 in total

1.  The treatment of expanding lesions of the orbit with particular regard to those arising in the lacrimal gland; the seventh Arthur J. Bedell lecture.

Authors:  A B REESE
Journal:  Am J Ophthalmol       Date:  1956-01       Impact factor: 5.258

2.  Carcinosarcoma of the lacrimal gland arising from a pleomorphic adenoma.

Authors:  Masayuki Takahira; Yasuhisa Nakamura; Shin-Ichi Shimizu; Hiroshi Minato; Nobutada Katori; Hiroshi Kobayashi; Yusuke Nakatani; Kazuhisa Sugiyama
Journal:  Am J Ophthalmol       Date:  2005-08       Impact factor: 5.258

3.  An epidemiological survey of lacrimal fossa lesions in Japan: number of patients and their sex ratio by pathological diagnosis.

Authors: 
Journal:  Jpn J Ophthalmol       Date:  2005 Sep-Oct       Impact factor: 2.447

4.  Malignant epithelial tumors of the lacrimal gland: a clinicopathologic study of 21 cases.

Authors:  R L Font; S L Smith; R G Bryan
Journal:  Arch Ophthalmol       Date:  1998-05

5.  Comprehensive management of a rare carcinoma ex pleomorphic adenoma of the lacrimal gland with a modified lateral orbitotomy access osteotomy. A case report.

Authors:  Yogesh K Kini; Rajshekhar Halli; Somen Mishra; Jitendra V Kalburge
Journal:  Oral Maxillofac Surg       Date:  2011-03-29

6.  Epithelial lacrimal gland tumors: pathologic classification and current understanding.

Authors:  Ezekiel Weis; Jack Rootman; Thomas J Joly; Kenneth W Berean; Hind M Al-Katan; Sylvia Pasternak; Giulio Bonavolontà; Diego Strianese; Peerooz Saeed; Kenneth A Feldman; Sumalee Vangveeravong; Jocelyne S Lapointe; Valerie A White
Journal:  Arch Ophthalmol       Date:  2009-08

7.  Unusual progression of pleomorphic adenoma of the lacrimal gland: case report.

Authors:  Takeshi Miyazaki; Toshiki Yamasaki; Kouzo Moritake; Yoshifumi Matsumoto; Yasuhiko Akiyama; Hidemasa Nagai; Yoshiaki Yamamoto; Tatsuo Kodama
Journal:  Neurol Med Chir (Tokyo)       Date:  2005-08       Impact factor: 1.742

8.  Histopathological classification of 272 primary epithelial tumors of the lacrimal gland.

Authors:  C Ni; P K Kuo; T P Dryja
Journal:  Chin Med J (Engl)       Date:  1992-06       Impact factor: 2.628

9.  Atypical presentations of pleomorphic adenoma of the lacrimal gland.

Authors:  M Reza Vagefi; Jenny E Hong; Orin M Zwick; Edward H Bedrossian; Stuart R Seiff; Kimberly P Cockerham
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2007 Jul-Aug       Impact factor: 1.746

Review 10.  Epithelial tumors of the lacrimal gland: an update.

Authors:  Francesco P Bernardini; Martìn H Devoto; J Oscar Croxatto
Journal:  Curr Opin Ophthalmol       Date:  2008-09       Impact factor: 3.761

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.